|
Multiple sclerosis
Citations 81-90 of 469 total displayed.
|
Past content
(since Jan 2001):
|
- EDITORIALS
Picturing injury and recovery with diffusion tensor imaging: The eyes have it
- Robert A. Bermel and Robert J. Fox
Neurology 2009; 72: 584-585.
[Full text]
[PDF]
- EDITORIALS
Brain atrophy as an outcome measure for multiple sclerosis clinical trials: A "no-brainer"?
- Richard A. Rudick and Elizabeth Fisher
Neurology 2009; 72: 586-587.
[Full text]
[PDF]
- ARTICLES
Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities
- R. T. Naismith, J. Xu, N. T. Tutlam, A. Snyder, T. Benzinger, J. Shimony, J. Shepherd, K. Trinkaus, A. H. Cross, and S-K Song
Neurology 2009; 72: 589-594.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
- D. R. Altmann, B. Jasperse, F. Barkhof, K. Beckmann, M. Filippi, L. D. Kappos, P. Molyneux, C. H. Polman, C. Pozzilli, A. J. Thompson, K. Wagner, T. A. Yousry, and D. H. Miller
Neurology 2009; 72: 595-601.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Demyelinating events in early multiple sclerosis have inherent severity and recovery
- E. M. Mowry, M. Pesic, B. Grimes, S. Deen, P. Bacchetti, and E. Waubant
Neurology 2009; 72: 602-608.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
- J. A. Cohen, P. B. Imrey, P. A. Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton, III, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, G. J. Hutton, B. F. Mandell, T. F. Scott, H. Zhang, C. Apperson-Hansen, G. J. Beck, P. L. Houghtaling, M. T. Karafa, M. Stadtler For the ACT Investigators
Neurology 2009; 72: 535-541.
[Abstract]
[Full text]
[PDF]
- VIEWS AND REVIEWS
Epistasis: Multiple sclerosis and the major histocompatibility complex
- Sreeram V. Ramagopalan and George C. Ebers
Neurology 2009; 72: 566-567.
[Full text]
[PDF]
- EDITORIALS
Natalizumab: Bound to rebound?
- Nicoline Schiess and Peter A. Calabresi
Neurology 2009; 72: 392-393.
[Full text]
[PDF]
- ARTICLES
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
- O. Stüve, P. D. Cravens, E. M. Frohman, J. T. Phillips, G. M. Remington, G. von Geldern, S. Cepok, M. P. Singh, J. W. Cohen Tervaert, M. De Baets, D. MacManus, D. H. Miller, E. W. Radü, E. M. Cameron, N. L. Monson, S. Zhang, R. Kim, B. Hemmer, and M. K. Racke
Neurology 2009; 72: 396-401.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- B. O. Khatri, S. Man, G. Giovannoni, A. P. Koo, J-C Lee, B. Tucky, F. Lynn, S. Jurgensen, J. Woodworth, S. Goelz, P. W. Duda, M. A. Panzara, R. M. Ransohoff, and R. J. Fox
Neurology 2009; 72: 402-409.
[Abstract]
[Full text]
[PDF]
|
|
